Snapshot of Broker-Favored ASX Shares
This week’s brokerage insights have brought to the forefront three ASX-listed companies considered favorable picks for investors. Let’s delve into these selections and understand their potential for the upcoming week.
Coles Group Ltd (ASX: COL)
Morgans has retained an add rating for Coles Group with an increased price target of $18.95, applauding the robust sales in its third quarter. With a 4.2% growth surpassing predicted figures and edging out competition, the supermarket giant appears poised for market share gains, despite potential cost inflation challenges.
ResMed Inc. (ASX: RMD)
Following an impressive quarterly performance, Citi maintains a buy rating for ResMed with a price target lift to $38.00. Notable margin improvements and expectations of minimal market competition until 2026 put ResMed in a favorable growth trajectory, especially with growing awareness for sleep disorder treatments.
Woolworths Group Ltd (ASX: WOW)
With a price target adjustment to $39.40, Goldman Sachs continues to recommend Woolworths as a conviction buy. The third quarter sales, matching predictions, have led analysts to anticipate a positive shift in market share trends, suggesting its current share price may undervalue the company’s outlook.
Insights and Concluding Thoughts
The mentioned companies showcase strategic market positions and growth potential as per top brokerage analysis. Coles’ sales performance and ResMed’s competitive advantage highlight promising market presences, while Woolworths’ positioning suggests a potential rebound. Investors may find these insights valuable as they contemplate portfolio adjustments for the coming week.